OCUPRESS
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
May 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OCUPRESS by Novartis is clinical pharmacology carteolol hcl is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. First approved in 1990.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCUPRESS (carteolol HCl) is a nonselective beta-adrenergic blocker ophthalmic solution indicated for reducing intraocular pressure in glaucoma and ocular hypertension. It works by reducing aquatic humor production through beta-adrenergic blockade, achieving a median 22-25% IOP reduction in clinical trials. The drug is administered topically as eye drops twice daily.
LOE Approaching
As a mature ophthalmic product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely transitioning to cost management and line extension strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Carteolol HCl is a nonselective beta-adrenergic blocking agent with associated intrinsic sympathomimetic activity and without significant membrane-stabilizing activity. Ocupress (carteolol HCl) reduces normal and elevated intraocular pressure (IOP) whether or not accompanied…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OCUPRESS in its LOE-approaching phase offers valuable experience in mature product management, generic defense strategies, and portfolio rationalization—critical skills for pharma professionals. Career progression typically moves toward specialty therapeutics or higher-growth ophthalmic products rather than remaining on established brands.
Worked on OCUPRESS at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.